Literature DB >> 33640070

Endometriosis is a chronic systemic disease: clinical challenges and novel innovations.

Hugh S Taylor1, Alexander M Kotlyar2, Valerie A Flores2.   

Abstract

Endometriosis is a common disease affecting 5-10% of women of reproductive age globally. However, despite its prevalence, diagnosis is typically delayed by years, misdiagnosis is common, and delivery of effective therapy is prolonged. Identification and prompt treatment of endometriosis are essential and facilitated by accurate clinical diagnosis. Endometriosis is classically defined as a chronic, gynaecological disease characterised by endometrial-like tissue present outside of the uterus and is thought to arise by retrograde menstruation. However, this description is outdated and no longer reflects the true scope and manifestations of the disease. The clinical presentation is varied, the presence of pelvic lesions is heterogeneous, and the manifestations of the disease outside of the female reproductive tract remain poorly understood. Endometriosis is now considered a systemic disease rather than a disease predominantly affecting the pelvis. Endometriosis affects metabolism in liver and adipose tissue, leads to systemic inflammation, and alters gene expression in the brain that causes pain sensitisation and mood disorders. The full effect of the disease is not fully recognised and goes far beyond the pelvis. Recognition of the full scope of the disease will facilitate clinical diagnosis and allow for more comprehensive treatment than currently available. Progestins and low-dose oral contraceptives are unsuccessful in a third of symptomatic women globally, probably as a result of progesterone resistance. Oral gonadotropin-releasing hormone (GnRH) antagonists constitute an effective and tolerable therapeutic alternative when first-line medications do not work. The development of GnRH antagonists has resulted in oral drugs that have fewer side-effects than other therapies and has allowed for rapid movement between treatments to optimise and personalise endometriosis care. In this Review, we discuss the latest understanding of endometriosis as a systemic disease with multiple manifestations outside the parameters of classic gynaecological disease.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33640070     DOI: 10.1016/S0140-6736(21)00389-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

1.  [Lowered expression of CCN5 in endometriotic tissues promotes proliferation, migration and invasion of endometrial stromal cells].

Authors:  H Cai; M Liu; M Lin; H Li; L Shen; S Quan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

2.  The importance of vitamin D in the diagnosis and treatment of adenomyosis.

Authors:  Rymgul S Moldassarina; Gulshat K Manabayeva; Zhansulu Ye Akylzhanova; Azima M Rashidova
Journal:  Mol Cell Biochem       Date:  2022-08-11       Impact factor: 3.842

3.  Early growth response 1 transcription factor is essential for the pathogenic properties of human endometriotic epithelial cells.

Authors:  Vineet K Maurya; Maria M Szwarc; Rodrigo Fernandez-Valdivia; David M Lonard; Song Yong; Niraj Joshi; Asgerally T Fazleabas; John P Lydon
Journal:  Reproduction       Date:  2022-06-27       Impact factor: 3.923

4.  Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial.

Authors:  Hugh Taylor; Howard J Li; Sandra Carson; Valerie Flores; Lubna Pal; Jared Robbins; Nanette F Santoro; James H Segars; David Seifer; Hao Huang; Steven Young; Heping Zhang
Journal:  BMJ Open       Date:  2022-06-17       Impact factor: 3.006

5.  Effectiveness of gonadotrophin-releasing hormone agonist therapy to improve the outcomes of intrauterine insemination in patients suffering from stage I-II endometriosis.

Authors:  Kemei Zhang; Shisi Huang; Haiyan Xu; Jiaou Zhang; Ensheng Wang; Yang Li; Changling Zhu; Jing Shu
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

6.  Endometriosis and cardiovascular disease.

Authors:  Benjamin Marchandot; Anais Curtiaud; Kensuke Matsushita; Antonin Trimaille; Aline Host; Emilie Faller; Olivier Garbin; Chérif Akladios; Laurence Jesel; Olivier Morel
Journal:  Eur Heart J Open       Date:  2022-02-02

7.  Endometriosis promotes atherosclerosis in a murine model.

Authors:  Ramanaiah Mamillapalli; Nikoletta Toffoloni; Shutaro Habata; Huang Qunhua; Rula Atwani; Nina Stachenfeld; Hugh S Taylor
Journal:  Am J Obstet Gynecol       Date:  2022-03-26       Impact factor: 10.693

Review 8.  Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.

Authors:  Abdelrahman AlAshqar; Lauren Reschke; Gregory W Kirschen; Mostafa A Borahay
Journal:  Biol Reprod       Date:  2021-07-02       Impact factor: 4.285

Review 9.  Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets?

Authors:  Luciana Cacciottola; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

10.  Activation of Hypocretin Neurons in Endometriosis.

Authors:  Ramanaiah Mamillapalli; Tran Dang; Shutaro Habata; Xiao-Bing Gao; Hugh S Taylor
Journal:  Reprod Sci       Date:  2021-07-19       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.